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POSTURAL DRAINAGE OR FLUTTER® DEVICE IN
CONJUNCTION WITH BREATHING AND COUGHING
COMPARED TO BREATHING AND COUGHING ALONE IN
IMPROVING SECRETION REMOVAL AND LUNG FUNCTION IN
PATIENTS WITH ACUTE EXACERBATION OF
BRONCHIECTASIS: A PILOT STUDY
Sharon M.H. Tsang, MSc, BSc PT; Alice Y.M. Jones,1 PhD, FACP, MSc, MPhil, Cert PT
Abstract: Maximizing normal coughing, the single best means for clearing pulmonary secretions and protecting
the lung, is a primary focus of physiotherapy in patients with impaired mucociliary clearance. In busy Hong
Kong hospitals, patients are often encouraged to use breathing and coughing (BC) manoeuvres, in conjunction
with other techniques such as postural drainage (PD) and the use of the Flutter® device (FL), as self-treatment
to mobilize secretions. This pilot study examined whether the effects of PD and FL on secretion clearance and
lung function indices in patients with acute exacerbations of bronchiectasis were greater than that of BC alone.
Fifteen patients admitted with bronchiectasis were randomly allocated to three groups: PD+BC, FL+BC and
BC alone. Treatment was applied for 15 minutes daily in all groups, until the day of discharge. Variables measured
included wet weight sputum production (during the 15-minute treatment time, during the subsequent 15-minute
post-treatment period, and over 24 hours), forced vital capacity, forced expiratory volume in 1 second, and
peak expiratory flow rate. Variables were recorded on Days 2 and 4 after admission and on the day of discharge.
Patients were asked to allocate subjective ease and effectiveness scores for their treatment method. There was
no difference in sputum production or lung function parameters among the three groups at any of the measurement
points. Patients reported that all techniques were equally easy to use, but FL was perceived as being the most
effective in clearing secretions. PD and FL do not appear to facilitate secretion removal beyond that achieved
by BC alone.
Key words: postural drainage, breathing manoeuvres, coughing manoeuvres, Flutter® device,
secretion mobilization
Introduction
Bronchiectasis is a condition characterized by permanent
abnormal dilatation and distortion of bronchi [1]. Patients
often have diminished bronchial mucociliary function,
Research Report
sputum retention and recurrent pulmonary infections,
which are the cause of hospitalizations [2–4]. With
advances in pharmacology, surgery and genetic
counselling over the past few decades, the prevalence of
both congenital and acquired bronchiectasis has been
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greatly reduced [5]. However, bronchiectasis still accounts
for 5% of hospital admissions relating to respiratory
conditions in Hong Kong [6].
Airway secretions, particularly those in peripheral
airways, require a forced expiratory manoeuvre for
expectoration. To facilitate passage of air to alveoli
beyond the secretions, a deep breathing manoeuvre is
adopted prior to the application of forced expiratory
techniques. Coughing is a common forced expiratory
manoeuvre adopted by patients for expectoration of
secretions from the central airways [7, 8]. Mobilization,
body positioning and deep breathing and coughing (BC)
are physiological manoeuvres commonly prescribed to
patients for removal of excessive pulmonary secretions [9].
Postural drainage (PD) is a technique that facilitates
mobilization of pulmonary secretions by employing the
effect of gravity [10]. Its effectiveness, however, has
most often been evaluated in combination with other
techniques such as percussion and vibration [11, 12].
The Flutter® valve (FL; model VRP1, Vario Raw SA,
Aubonne, Switzerland) was introduced in early 1980.
This small device was designed to generate controlled
airflow oscillation during the respiratory cycle with a
maximum positive expiratory pressure of 20 cmH2O
(manufacturer’s manual). The frequency of oscillation is
believed to increase the expiratory flow of pulmonary
secretions and to facilitate their movement from
peripheral to more central airways. The effectiveness of
secretion mobilization using the FL has been reported as
comparable to conventional PD and percussion, but
these studies mostly report effects of combined techniques
in patients with asthma [13, 14], cystic fibrosis [15–19]
and chronic bronchitis [20, 21]. To our knowledge, there
has been only one report of the effect of PD in patients
with bronchiectasis [22].
PD usually requires the use of a bed and passive
positioning of the body, while the FL, though convenient
and more dynamic in its application, costs around HK$250
per piece. The advantage of combining PD or the FL with
BC is that they can be used by the patient as a form of self-
treatment to facilitate secretion mobilization. This study
used a randomized, controlled, single-blinded design to
determine whether conventional PD and the FL, when
combined with BC, had any effect on secretion
mobilization in patients with an acute exacerbation of
bronchiectasis, over and above BC alone.
Methods
This was a randomized clinical study with repeated
measurements of outcome indicators. Ethical approval
was obtained from the hospital prior to commencement
of the study.
Patients admitted to the hospital and diagnosed with
an acute exacerbation of bronchiectasis were invited to
participate in the study. Inclusion criteria included a
confirmed diagnosis of bronchiectasis of at least 1 year’s
duration, presentation with symptoms of persistent cough
and sputum production, and age above 20 but below 65
years. Exclusion criteria included an inability to use the
portable spirometer for lung function measurement,
acute haemoptysis, chest pain, pneumothorax and
coexisting known cardiovascular or neurological disease.
All patients were screened by the attending physician.
The potential risks and benefits, as well as the procedures
involved in the study, were explained to patients. Written
consent was obtained and a training session on the use
of the spirometer conducted prior to data collection.
Patients recruited were randomized into three groups
by drawing lots. Patients in the PD+BC group were
instructed (by a physiotherapist) to adopt a maximum of
two gravity-dependent positions for drainage of secretions
for a total duration of 15 minutes. The choice of positions
was based on information from chest radiographs and
auscultation of the chest by the physiotherapist. During
this 15-minute “treatment” session, patients were asked
to perform BC every 3 minutes. BC consisted of a cycle
of five slow, deep, inspiratory breaths through the nose
(aiming to expand the base of the lungs without
inspiratory hold), followed by relaxed expiration. This
manoeuvre was then followed by one voluntary cough,
followed by normal relaxed breathing.
Patients in the FL+BC group were taught (by the
same physiotherapist) the proper use of the FL in the
sitting position for 15 minutes. Patients were instructed
to inhale normally through the mouth and expire through
the FL. The angle of inclination of the FL mouthpiece
was adjusted so that maximal resonance of the chest wall
was felt by the patient and concurrently palpated by the
physiotherapist. During the 15-minute duration of
treatment, the patient was asked to perform a cycle, every
3 minutes, of five deep breaths, expired through the FL,
then one voluntary cough followed by breathing control.
Patients in the BC group were taught to perform a
cycle of five deep breaths followed by a cough and
breathing control (as in the PD+BC group but in the
sitting position) every 3 minutes for 15 minutes.
All protocols were carried out once per day, under
the supervision of the same physiotherapist, from the
second day of admission (Day 2) until discharge. Patients
were instructed to continue with the taught treatment
protocol two more times per day (without supervision),
and cough as necessary to expectorate sputum. Lung
function parameters, including forced vital capacity
(FVC), forced expiratory volume in 1 second (FEV1) and
peak expiratory flow rate (PEFR), were recorded using a
spirometer (Micro-spirometer MS01, Micro Medical Ltd,
Gillingham, Kent, UK) on Day 1, before treatment, and
then before and after each treatment on Days 2 and 4 and
the day of discharge. The wet weight of sputum
expectorated during the 15-minute treatment session
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(S15), during the 15 minutes after treatment (S30) and
at 24 hours (i.e. for the 23.5 hours after S30) were
measured using a calibrated electronic scale (Ohaus
Explorer®, Ohaus Corporation, Pine Brook, NJ, USA).
The total amount of sputum expectorated in the 24
hours (i.e. including S15 and S30) was labelled S24.
These parameters (S15, S30 and S24) were recorded on
Days 2 and 4 and the day of discharge. The heart rate and
oxygen saturation of the patient during each treatment
were monitored with a pulse oximeter (Pulsox-3, Minolta
Co Ltd, Osaka, Japan) during treatment.
After every supervised treatment, patients were asked
to complete a subjective 4-point Likert scale ranging
from “not effective at all” to “very effective” for the
effectiveness of the treatment protocol, and “very easy”
to “very difficult” for the degree of ease of application of
the treatment modality they received.
Equipment calibration
Prior to data collection, the micro-spirometer was
calibrated using a 2 L super-syringe method at 25°C.
During data collection, the best of three trials of
measurements was recorded from each patient for
analysis. All measurements were performed in the sitting
position.
Statistical analysis
Baseline parameters among the three groups were
compared using one-way analysis of variance (one-way
ANOVA). Repeated measures of analysis of variance
(RANOVA) were used to compare both the within- and
between-subject effects on pulmonary function indices
after treatment, and the amount of secretion cleared
over the data collection period [23]. The level of
significance was set at 0.05. Data analysis was performed
using SPSS version 10 (SPSS Inc, Chicago, IL, USA).
Results
A total of 26 patients were admitted to hospital with an
acute exacerbation of bronchiectasis during the
recruitment period. Eleven of these patients were
excluded because of haemoptysis, because they were
unable to manage the spirometric lung function testing,
or because their illness was complicated by myocardial
infarction. The mean duration of hospitalization was
similar in the PD+BC, FL+BC and BC groups: 7.2 (± 3.3),
6.2 (± 3.83) and 5.2 (± 0.84) days, respectively (p = 0.58).
There were no differences among the three groups in
age, body weight and height, gender distribution, duration
of disease, amount of sputum produced in the first 24
hours after admission and pulmonary function indices
(p > 0.05). There were more smokers in the BC group
compared to the PD+BC and FL+BC groups. The
demographic data of subjects are shown in Table 1.
The difference in the wet weight of sputum
expectorated over the 24-hour periods on Days 2 and 4
and the day of discharge among the three groups was not
significant. The amount of sputum expectorated during
the treatment time (S15) and the 15 minutes post
treatment (S30) was also expressed as a percentage of the
total sputum produced over the 24-hour period, but there
was no difference among the three groups (Table 2).
There were no significant changes in the measured
lung function indices before and after each treatment
nor across the three treatment groups (Table 3). There
was no difference in the subjective score for ease of
Table 1. Description of subjects
Group PD+BC (M:F = 2:3) FL+BC (M:F = 3:2) BC (M:F = 3:2) p
Age (yr) 66.80 (15.48) 72.40 (5.27) 74.20 (6.37) 0.504
Body weight (kg) 49.45 (7.09) 48.72 (8.93) 49.73 (9.54) 0.982
Height (m) 1.53 (0.11) 1.54 (0.05) 1.58 (0.09) 0.730
Years since diagnosis 18.40 (11.84) 14.60 (12.05) 11.00 (5.48) 0.539
Smoker (frequency) 1 3 4 NA
Years of smoking 5.40 (12.07) 6.20 (13.30) 18.40 (13.29) 0.235
Sputum in first 24 hr (g) 47.53 (23.24) 25.56 (14.66) 26.18 (20.29) 0.176
FVC (L) 1.03 (0.46) 0.90 (0.34) 0.82 (0.34) 0.694
FVC (% predicted) 47.69 (22.16) 41.56 (9.60) 36.55 (10.47) 0.528
FEV
1
 (L) 0.79 (0.48) 0.60 (0.17) 0.55 (0.19) 0.473
FEV
1
 (% predicted) 48.47 (23.97) 39.45 (7.07) 36.10 (11.08) 0.463
PEFR (L/min) 154.20 (111.66) 90.00 (39.62) 113.00 (43.82) 0.398
PEFR (% predicted) 47.96 (28.68) 29.29 (10.14) 37.36 (9.98) 0.313
Data are mean (standard deviation) except for the number of smokers (frequency). PD = postural drainage; BC = breathing and coughing;
M = male; F = female; FL = Flutter® device; FVC = forced vital capacity; FEV
1
 = forced expiratory volume in 1 second; PEFR = peak expiratory
flow rate.
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application of each of the treatment modalities. However,
post-hoc analysis demonstrated that the scores for degree
of effectiveness in the FL+BC group were higher than
those in the BC group on each of the treatment days
(p < 0.05), while there was no difference between the
scores in the PD+BC and FL+BC groups (Table 4).
There were no changes in either the heart rate or
oxygen saturation during treatment in any of the groups.
Discussion
This study showed a decreasing amount of secretion
expectorated over the hospitalization period for all
patients, irrespective of the method used to enhance
secretion removal. This is perhaps not surprising because
the major factor causing increased sputum production is
infection, for which the most effective treatment is
appropriate antibiotics at effective concentrations. The
preponderant effect of antibiotics may have masked any
secondary differences between the various sputum
clearance  augmentat ion techniques  dur ing
hospitalization.
PD has conventionally been used by physiotherapists
to assist secretion removal in patients. Recent research
has demonstrated that positioning and mobilization are
most efficient in facilitation of oxygen transport [24],
and mobilization combined with coughing and deep
breathing manoeuvres has been suggested as a primary
treatment intervention to promote airway clearance
[25]. In our experience, although the effect of positioning
and mobilization has been well documented, PD and
other traditional methods of secretion removal, such as
the use of the FL, are still frequently employed in busy hos-
pitals in Hong Kong for patients with excessive secretions.
The practical application of the PD technique is
restricted, for example, when the patient is at work or
has conditions, such as ischaemic heart disease and
hypertension, where the head-down position is
contraindicated. In Hong Kong hospitals, PD is often
introduced to patients as a form of self-treatment
combined with BC prior to discharge from hospital. The
FL is a useful form of self-treatment in secretion
mobilization, comparable to PD [15, 16, 26, 27].
Often, in Hong Kong hospitals, only 15 minutes of
treatment time are available for each patient. Protocols
for secretion removal employed during this treatment
time are PD or use of the FL combined with BC
manoeuvres. Our study therefore adopted similar
protocols, standardizing the BC manoeuvres as cycles of
five slow breaths followed by a cough repeated every 3
minutes in all treatment groups. A rigid protocol for
standardization of the manoeuvres was adopted for this
research. However, in clinical situations, the “cycle” of
the BC manoeuvre, although employed in a similar
fashion, would be more flexible.
Table 2. Wet weight of sputum collected during treatment (S15), 15 minutes post treatment (S30) and over the
24-hour period (S24) on Days 2 and 4 and the day of discharge
PD+BC FL+BC BC p
Day 2
  S15 (g) 3.87 (4.40) 4.45 (4.61) 0.89 (0.62) 0.299
  S30 (g) 1.53 (2.04) 0.24 (0.54) 0 0.146
  S24 (g) 45.34 (26.48) 25.48 (17.47) 26.19 (25.13) 0.345
  S15/S24% 10.98 (10.36) 17.65 (18.28) 6.36 (7.93) 0.411
  S30/S24% 2.37 (2.42) 1.94 (4.35) 0 0.408
Day 4
  S15 (g) 3.65 (7.44) 1.57 (1.67) 0.43 (0.61) 0.524
  S30 (g) 0.04 (0.10) 0.20 (0.45) 0 0.476
  S24 (g) 36.35 (35.67) 13.89 (12.64) 18.77 (18.67) 0.447
  S15/S24% 13.53 (24.91) 12.21 (15.08) 5.37 (8.48) 0.737
  S30/S24% 0.15 (0.34) 1.78 (3.99) 0 0.426
Day of discharge
  S15 (g) 4.99 (5.48) 1.53 (1.72) 0.45 (0.63) 0.123
  S30 (g) 0.99 (2.09) 0.20 (0.45) 0 0.434
  S24 (g) 34.99 (34.65) 13.96 (12.60) 19.48 (18.97) 0.422
  S15/S24% 23.47 (22.70) 11.59 (15.60) 5.78 (8.66) 0.270
  S30/S24% 1.78 (2.24) 1.78 (1.26) 0 0.570
Data are mean (standard deviation). PD = postural drainage; BC = breathing and coughing; FL = Flutter® device.
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Only one study has reported the effectiveness of PD
in patients with bronchiectasis. Mazzocco and colleagues
found that patients produced as much as 48% of the
total daily sputum during a 10-minute PD session [22].
This sputum volume was double our findings (11–23.5%
over the different days). Mazzocco et al’s patients were
recruited from outpatient units and had a wide range of
baseline pulmonary function. For example, their FVC
ranged from 16% to 111% of the predicted value, FEV1
ranged from 26% to 95%, and PEFR ranged from 28%
to 139% predicted. Our subjects were recruited during
an acute exacerbation of disease within a much narrower
range of indices of lung function. These substantive
differences make any comparison with Mazzocco et al’s
study meaningless.
PD has been shown to be effective in facilitating the
movement of secretions from peripheral airways [17].
Interestingly, Lannefors and colleagues reported maximal
removal of inhaled particles from dependent, rather
than non-dependent, parts of the lung, and suggested
that the effect of gravity was not the main determinant
of mucus clearance, but that the effect of regional
ventilation and perfusion in promotion of mucus
mobilization was often underestimated [17]. The positive
Table 3. Lung function changes before and after treatment on each of the measurement days
PD+BC FL+BC BC p
FVC (L)
  Day 2 Pre-treatment 0.99 (0.41) 0.94 (0.38) 0.81 (0.35) 0.069
Post-treatment 0.92 (0.42) 1.14 (0.52) 0.85 (0.41)
  Day 4 Pre-treatment 1.15 (0.69) 1.06 (0.31) 0.89 (0.46) 0.639
Post-treatment 1.26 (0.72) 1.06 (0.29) 0.90 (0.47)
  Day D/C Pre-treatment 1.17 (0.68) 1.10 (0.28) 0.88 (0.44) 0.798
Post-treatment 1.19 (0.68) 1.07 (0.28) 0.89 (0.45)
FEV
1
 (L)
  Day 2 Pre-treatment 0.78 (0.46) 0.62 (0.20) 0.56 (0.21) 0.790
Post-treatment 0.76 (0.47) 0.64 (0.16) 0.55 (0.22)
  Day 4 Pre-treatment 0.81 (0.48) 0.62 (0.14) 0.58 (0.30) 0.302
Post-treatment 0.79 (0.44) 0.64 (0.18) 0.60 (0.28)
  Day D/C Pre-treatment 0.83 (0.47) 0.65 (0.16) 0.59 (0.32) 0.843
Post-treatment 0.83 (0.43) 0.65 (0.19) 0.61 (0.31)
PEFR (L/min)
  Day 2 Pre-treatment 146.2 (76.69) 89.0 (38.84) 119.0 (49.20) 0.177
Post-treatment 136.0 (70.77) 113.8 (39.59) 119.0 (51.39)
  Day 4 Pre-treatment 139.8 (80.18) 112.0 (58.93) 132.2 (68.17) 0.691
Post-treatment 131.4 (54.38) 108.8 (47.5) 136.0 (74.92)
  Day D/C Pre-treatment 147.6 (76.91) 117.0 (59.94) 137.2 (77.75) 0.829
Post-treatment 141.2 (49.65) 118.0 (51.59) 138.6 (79.8)
Data are mean (standard deviation). PD = postural drainage; BC = breathing and coughing; FL = Flutter® device; FVC = forced vital capacity;
FEV
1
 = forced expiratory volume in 1 second; PEFR = peak expiratory flow rate; D/C = discharge.
Table 4. Subjective degree of effectiveness scores for the three treatment modalities
PD+BC FL+BC BC p
Day 2 3.0 (0) 3.0 (0) 2.4 (0.55) 0.016*
Day 4 3.0 (0) 3.4 (0.55) 2.4 (0.55) 0.013*
Day D/C 3.0 (0) 3.4 (0.55) 2.4 (0.55) 0.013*
Overall mean 3.0 (0) 3.27 (0.37) 2.4 (0.51) 0.011*
Data are mean (standard deviation). PD = postural drainage; BC = breathing and coughing; FL = Flutter® device; D/C = discharge. *p < 0.05.
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effect of upright and non-dependent positions in the
promotion of matching of ventilation and perfusion has
been well documented [28–32]. Our daily totals and
amount of sputum produced during the 15-minute
treatment times were similar for all treatment methods,
supporting Lannefors et al’s view that the effect of gravity
on secretion movement may be overestimated [17].
The effect of PD on secretion clearance persists for a
few hours after the termination of treatment [11, 33].
Mucus in peripheral regions takes time to mobilize to
central airways for expectoration. We therefore measured
sputum production 15 minutes post-treatment. Our
findings, however, demonstrated no further sputum
expectorated during the monitored post-treatment period
in the BC group, and only a small amount of sputum was
produced by patients in the other two groups. This
suggests that any immediate post-treatment effect using
our treatment protocols was minimal.
Coughing is a physiological means of airway clearance
[7, 8]. It has been suggested that in patients with
bronchiectasis and chronic bronchitis where secretions
are the predominant problem, coughing is responsible
for 50% of airway clearance [8, 34]. Coughing, as
opposed to huffing, was taught to the patients in this
study because many of them had had bronchiectasis for
more than 10 years and were more familiar with
conventional BC than with the huffing technique. It was
the aim of this study to compare the effectiveness of
conventional methods in secretion clearance employed
in local hospitals.
Our pilot study suggests that there is no additional
benefit to be gained by combining BC with either PD or
the use of the FL.
If the techniques had assisted secretion clearance, it
would be anticipated that FEV1 and PEFR would improve
as the airway became less obstructed by sputum.
However, we were not able to demonstrate any significant
changes in any lung function parameters after any
treatment session, or any differences between the three
groups. The long-term effects of PD and FL on lung
function indices have been reported over 13 treatment
days with follow-up periods of 3 years [13, 20, 35–39].
In the current study, the mean duration of stay in
hospital was 6 days. It is possible that improvement in
lung function in our patients was masked by the acute
infective condition and antibiotic treatment [40].
Subjective level of comfort and acceptance of a
treatment modality by patients is an important
consideration when maximizing patient compliance [41–
43]. Our subjects considered all three methods equally
easy to follow, but subjectively found FL+BC to be more
effective than BC alone in secretion clearance. This may
have been influenced by the security provided by the
physiotherapist’s attendance during PD and FL, increasing
their confidence in the modality, whereas BC was a
technique they had been practising for years.
This pilot study was undertaken to determine whether
there was a significant difference when BC was employed
with one of two other conventional secretion removal
techniques and to suggest the sample size necessary for
that difference to be significant. Mean data showed large
standard deviations, and, consequently, the effect size
for some comparisons was less than 0.36. For this study
to demonstrate a significant difference in sputum
production between the groups and achieve 80% power
with an alpha value of 5%, a sample size of approximately
30 subjects per group would be necessary (Power Analysis
& Sample Size for Windows, version 6.0, NCSS, Kaysville,
UT, USA).
Limitations of the Study
The major limitation of this study was the failure to
standardize patient mobility between the groups, as
mobilization and upright position influence removal of
airway secretions [25]. Further investigation is necessary
to determine whether BC has additional benefit over
mobilization alone in patients with an acute exacerbation
of bronchiectasis.
To demonstrate the effect of PD, FL or BC manoeuvres,
a control group without treatment intervention is
necessary, but currently, this is ethically untenable in
Hong Kong. Although such treatment is considered
ethical practice, a focus on sputum clearance has been
questioned in that its association with improved lung
function and blood gases is inconsistent. Thus, treatment
has shifted toward a focus on oxygen transport overall and
away from a primary focus on airways and lungs [44].
Conclusions
To our knowledge, there has been no report comparing
the effect of PD or FL in conjunction with BC with that
of BC alone in patients with bronchiectasis. This pilot
study suggests that a cohort of 90 subjects is needed for
sufficient statistical power to demonstrate any additional
benefits of PD or FL over BC alone in patients with an
acute exacerbation of bronchiectasis. One can argue,
however, that low power is more clinically relevant in
that in the clinical situation, the physiotherapist deals
with an “n = 1”.
The results of this study suggest that neither PD nor
use of the FL when combined with BC has any additional
benefit over BC alone. The post-treatment effect of these
techniques was not apparent 15 minutes after treatment
and these techniques had no effect on lung function
indices immediately after treatment. Physiotherapists
need to carefully consider the allocation of their time
and the investment in prescribing evidence-based
interventions, including mobilization and exercise
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coupled with the upright position and breathing control,
in the management of the acutely ill patient to promote
secretion clearance, rather than a primary focus on PD
and the FL.
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